|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Smeltzer MP, Wynes MW, Lantuejoul S, Soo
R, Ramalingam SS, Varella-Garcia M, Meadows Taylor M, Richeimer K,
Wood K, Howell KE, et al: The international association for the
study of lung cancer global survey on molecular testing in lung
cancer. J Thorac Oncol. 15:1434–1448. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
American Cancer Society: Lung cancer
statistics: American Cancer Society available lung cancer
statistics: Available at: https://www.cancer.org/cancer/lung-cancer/about/what-is.html#:~:text=About%2080%25%20to%2085%25%20of,(outlook)%20are%20often%20similar.
|
|
6
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Crinò L, Weder W, van Meerbeeck J and
Felip E: ESMO Guidelines Working Group. Early stage and locally
advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 21 (Suppl 5):v103–v115. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Economopoulou P and Mountzios G: The
emerging treatment landscape of advanced non-small cell lung
cancer. Ann Transl Med. 6(138)2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ,
Dobelbower M, et al: Non-small cell lung cancer, version 5.2017,
NCCN clinical practice guidelines in oncology. J Natl Compr Cancer
Netw. 15:504–535. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
National Lung Screening Trial Research
Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom
RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD: Reduced
lung-cancer mortality with low-dose computed tomographic screening.
N Engl J Med. 365:395–409. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Planchard D, Popat S, Kerr K, Novello S,
Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD,
et al: Metastatic non-small cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 29 (Suppl 4):iv192–iv237. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Raez LE, Nogueira A, Santos ES, dos Santos
RS, Franceschini J, Ron DA, Block M, Yamaguchi N and Rolfo C:
Challenges in lung cancer screening in Latin America. J Glob Oncol.
4:1–10. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Raez LE, Cardona AF, Santos ES, Catoe H,
Rolfo C, Lopes G, Barrios C, Mas LA, Vallejos C, Zatarain-Barrón
ZL, et al: The burden of lung cancer in Latin-America and
challenges in the access to genomic profiling, immunotherapy and
targeted treatments. Lung Cancer. 119:7–13. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hirsch FR, Zaric B, Rabea A, Thongprasert
S, Lertprasertsuke N, Dalurzo ML and Varella-Garcia M: Biomarker
testing for personalized therapy in lung cancer in low- and
middle-income countries. Am Soc Clin Oncol Educ Book. 37:403–408.
2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kris MG, Johnson BE, Berry LD, Kwiatkowski
DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson
SL, Su PF, et al: Using multiplexed assays of oncogenic drivers in
lung cancers to select targeted drugs. JAMA.
311(1998)2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Arrieta O, Cardona AF, Martín C, Más-López
L, Corrales-Rodríguez L, Bramuglia G, Castillo-Fernandez O,
Meyerson M, Amieva-Rivera E, Campos-Parra AD, et al: Updated
frequency of EGFR and KRAS mutations in nonsmall-cell lung cancer
in Latin America: The Latin-American consortium for the
investigation of lung cancer (CLICaP). J Thorac Oncol. 10:838–843.
2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lindeman NI, Cagle PT, Beasley MB, Chitale
DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar J,
Squire J, et al: Molecular testing guideline for selection of lung
cancer patients for EGFR and ALK tyrosine kinase inhibitors:
Guideline from the College of American pathologists, international
association for the study of lung cancer, and association for
molecular pathology. J Thorac Oncol. 8:823–859. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chiang AC, Fernandes AW, Pavilack M,
Chiang AC, Wu JW, Laliberté F, Duh MS, Chehab N and Subramanian J:
EGFR mutation testing and treatment decisions in patients
progressing on first- or second-generation epidermal growth factor
receptor tyrosine kinase inhibitors. BMC Cancer.
20(356)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Oxnard GR, Arcila ME, Sima CS, Riely GJ,
Chmielecki J, Kris MG, Pao W, Ladanyi M and Miller VA: Acquired
resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung
cancer: Distinct natural history of patients with tumors harboring
the T790M Mutation. Clin Cancer Res. 17:1616–1622. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Soria-Comes T, Palomar-Abril V, Ureste MM,
Guerola MT and Maiques ICM: Real-world data of the correlation
between EGFR determination by liquid biopsy in non-squamous
non-small cell lung cancer (NSCLC) and the EGFR profile in tumor
biopsy. Pathol Oncol Res. 26:845–851. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Su PL, Yang SC, Chen YL, Wu YL, Lin CY,
Chang WY, Tseng YL, Lai WW, Ho CL, Lin CC and Su WC: Real-world
outcomes of NSCLC patients receiving tissue or circulating tumor
DNA-guided osimertinib treatment. Cancer Med. 8:5939–5947.
2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mhanna L, Guibert N, Milia J and Mazieres
J: When to consider immune checkpoint inhibitors in oncogene-driven
non-small cell lung cancer? Curr Treat Options Oncol.
20(60)2019.PubMed/NCBI View Article : Google Scholar
|
